Ubrogepant Safety in Migraine Patients With Cardiovascular Risk: CGRP Antagonist Reassurance
Ubrogepant (oral CGRP antagonist) showed acceptable safety and tolerability for acute migraine treatment in patients with cardiovascular risk factors, addressing a key safety concern.
Quick Facts
What This Study Found
Ubrogepant demonstrated acceptable safety and tolerability in migraine patients with cardiovascular risk factors, without increased cardiovascular events.
Key Numbers
Both drugs are oral CGRP receptor antagonists. Ubrogepant: acute treatment. Atogepant: preventive treatment.
How They Did This
Safety and tolerability analysis of ubrogepant in migraine patients with cardiovascular risk factors. Assessed cardiovascular events, adverse effects, and treatment outcomes.
Why This Research Matters
Millions of migraine patients have cardiovascular risk and cannot use triptans. Proving that CGRP antagonists like ubrogepant are safe in this population fills a major treatment gap.
The Bigger Picture
CGRP-targeted therapies are progressively proven safe across broader populations. This study extends the safety evidence to the specific group most in need — migraine patients who cannot take triptans due to cardiovascular risk.
What This Study Doesn't Tell Us
Safety analysis from specific trial data. Long-term cardiovascular safety in high-risk patients needs continued monitoring. Sample size may limit detection of very rare events.
Questions This Raises
- ?Should ubrogepant be first-line for migraine patients with cardiovascular disease?
- ?How does ubrogepant cardiovascular safety compare to gepant class competitors?
- ?Is long-term CGRP blockade safe for vascular health?
Trust & Context
- Key Stat:
- CV-safe migraine relief Ubrogepant safe in cardiovascular-risk migraine patients — critical for the millions who cannot use triptans due to heart risk
- Evidence Grade:
- Strong evidence: safety analysis in the specific population of concern, with no cardiovascular signal detected.
- Study Age:
- Published in 2024. Addresses a key safety question for CGRP antagonist prescribing.
- Original Title:
- Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study.
- Published In:
- Headache, 65(6), 1005-1014 (2025)
- Authors:
- Ailani, Jessica(4), Lipton, Richard B(9), Blumenfeld, Andrew M(3), Mechtler, Laszlo, Klein, Brad C, He, Molly Yizeng, Smith, Jonathan H, Trugman, Joel M, de Abreu Ferreira, Rosa, Brand-Schieber, Elimor
- Database ID:
- RPEP-09807
Evidence Hierarchy
Frequently Asked Questions
Can I take ubrogepant if I have heart disease?
This study shows ubrogepant was safe in migraine patients with cardiovascular risk factors — no increased heart events were seen. Unlike triptans, which are contraindicated with cardiovascular disease, CGRP antagonists like ubrogepant appear safe for these patients.
How is ubrogepant different from triptans?
Triptans constrict blood vessels (risky for cardiovascular patients). Ubrogepant blocks CGRP receptor signaling without constricting vessels, making it safe for migraine patients with heart disease, hypertension, or stroke history.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09807APA
Ailani, Jessica; Lipton, Richard B; Blumenfeld, Andrew M; Mechtler, Laszlo; Klein, Brad C; He, Molly Yizeng; Smith, Jonathan H; Trugman, Joel M; de Abreu Ferreira, Rosa; Brand-Schieber, Elimor. (2025). Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study.. Headache, 65(6), 1005-1014. https://doi.org/10.1111/head.14871
MLA
Ailani, Jessica, et al. "Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study.." Headache, 2025. https://doi.org/10.1111/head.14871
RethinkPeptides
RethinkPeptides Research Database. "Safety and tolerability of ubrogepant for the acute treatmen..." RPEP-09807. Retrieved from https://rethinkpeptides.com/research/ailani-2025-safety-and-tolerability-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.